Your browser doesn't support javascript.
loading
Outcomes of shoulder arthroplasty in haematopoietic stem cell transplant patients.
Statz, Joseph M; Chalmers, Brian P; Ledford, Cameron K; Sanchez-Sotelo, Joaquin; Sperling, John W; Morrey, Mark E.
Afiliación
  • Statz JM; Department of Orthopedic Surgery, Mayo Clinic, 200 First Street S.W, Rochester, MN, 55905, USA.
  • Chalmers BP; Department of Orthopedic Surgery, Mayo Clinic, 200 First Street S.W, Rochester, MN, 55905, USA.
  • Ledford CK; Department of Orthopedic Surgery, Mayo Clinic, 200 First Street S.W, Rochester, MN, 55905, USA.
  • Sanchez-Sotelo J; Department of Orthopedic Surgery, Mayo Clinic, 200 First Street S.W, Rochester, MN, 55905, USA.
  • Sperling JW; Department of Orthopedic Surgery, Mayo Clinic, 200 First Street S.W, Rochester, MN, 55905, USA.
  • Morrey ME; Department of Orthopedic Surgery, Mayo Clinic, 200 First Street S.W, Rochester, MN, 55905, USA. morrey.mark@mayo.edu.
Int Orthop ; 41(12): 2555-2564, 2017 12.
Article en En | MEDLINE | ID: mdl-28791443
BACKGROUND: With the growing population of patients undergoing haematopoietic stem cell transplants (HSCTs), the demand for shoulder arthroplasty (SA) in this population can be expected to increase. No studies in the literature have examined the outcomes of SA in HSCT patients. PATIENTS AND METHODS: A retrospective review of 11 SAs in 10 patients with previous HSCT was performed. We characterized the clinical outcomes, survivorship, and peri-operative complication rates in patients who underwent SA after receiving a HSCT. We also performed a subanalysis based on implant and transplant type. RESULTS: Seven of ten patients died with average two and five year post-operative patient survival rates of 70% +/- 14% and 47% +/- 17%, respectively. At average follow up of 4.2 years of the seven patients with two year followup, pain and range of motion improved with SA (p = 0.0625-0.2500). At final follow-up, five of seven shoulders were rated as satisfactory or excellent with modified Neer ratings. Two and five year survival rates free of re-operation were 100% +/- 0% and 67% +/- 27%, respectively. There were no other complications. No differences in outcomes were seen based on implant or transplant type besides RSA being associated with greater mortality risk (p = 0.0424, hazard ratio = 10.6). CONCLUSIONS: Patients with previous HSCT who undergo SA can expect to have good pain relief, range of motion improvement, subjective satisfaction, and low peri-operative complication rate with appropriate choice of implant. However, surgeons must inform patients about realistic post-operative outcomes given the high post-operative mortality rate. LEVEL OF EVIDENCE: Level IV, Prognosis.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Articulación del Hombro / Trasplante de Células Madre Hematopoyéticas / Artroplastia de Reemplazo Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int Orthop Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Articulación del Hombro / Trasplante de Células Madre Hematopoyéticas / Artroplastia de Reemplazo Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int Orthop Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania